XPO1 Inhibition Using Selinexor Synergizes With Chemotherapy in Acute Myeloid Leukemia (AML) by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus

PURPOSE: Selinexor, a selective inhibitor of XPO1, is currently being tested as single agent in clinical trials in acute myeloid leukemia (AML). However, considering the molecular complexity of AML, it is unlikely that AML can be cured with monotherapy. Therefore we asked whether adding already esta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ranganathan, Parvathi, Kashyap, Trinayan, Yu, Xueyan, Meng, Xiaomei, Lai, Tzung-Huei, McNeil, Betina, Bhatnagar, Bhavana, Shacham, Sharon, Kauffman, Michael, Dorrance, Adrienne M., Blum, William, Sampath, Deepa, Landesman, Yosef, Garzon, Ramiro
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161584/
https://ncbi.nlm.nih.gov/pubmed/27358488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2885
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados